Small molecule · Inhibitor of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) · developed by Pfizer
Palbociclib is a kinase inhibitor of cyclin-dependent kinases CDK4 and CDK6, which blocks progression of cells from the G1 into the S phase of the cell cycle. It acts on Rb phosphorylation and E2F signaling in hormone receptor-positive breast cancer. It is also being studied in HPV-unrelated head and neck squamous cell carcinoma.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 6, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04966481 | Phase 3 | HPV-unrelated Head and Neck Squamous Cell Carcinoma | Recruiting | PFE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
HPV-unrelated Head and Neck Squamous Cell Carcinoma
Updated Nov 15, 2026. Something wrong or missing? Report it on the PFE page.
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →